{"id":"ckd-828","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Anorexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CKD-828 selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1 (FGFR1), two key drivers of tumor angiogenesis and growth. By targeting both pathways simultaneously, the drug aims to overcome resistance mechanisms and provide enhanced anti-tumor activity in solid malignancies. This dual-target approach is designed to be more effective than single-pathway inhibitors in suppressing new blood vessel formation that tumors require for growth and metastasis.","oneSentence":"CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:14.103Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06112678","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-01-04","conditions":"Hypertension, Dyslipidemias","enrollment":63},{"nctId":"NCT04660370","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-01-09","conditions":"Hypertension and Dyslipidemia","enrollment":70},{"nctId":"NCT04883658","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2021-06-04","conditions":"Hypertension and Dyslipidemia","enrollment":62},{"nctId":"NCT05749861","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-04-22","conditions":"Hypertension and Dyslipidemia","enrollment":65},{"nctId":"NCT05881707","phase":"PHASE1","title":"A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828 20/1.25mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-07-04","conditions":"Hypertension","enrollment":44},{"nctId":"NCT05834595","phase":"PHASE1","title":"A Clinical Trial to Compare the Pharmacokinetic and Safety of CKD-828","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2023-05-02","conditions":"Hypertension","enrollment":43},{"nctId":"NCT05192356","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-02-23","conditions":"Hypertension and Dyslipidemia","enrollment":63},{"nctId":"NCT05549401","phase":"PHASE1","title":"Clinical Trial to Evaluate the Tolerability and the Pharmacokinetics of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-09-29","conditions":"Hypertension and Dyslipidemia","enrollment":32},{"nctId":"NCT05540912","phase":"PHASE1","title":"Exploratory Trial to Evaluate the Pharmacokinetic Properties and Safety of CKD-828 in Healthy Subjects","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-09-15","conditions":"Hypertension","enrollment":30},{"nctId":"NCT04587206","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-10-15","conditions":"Hypertension and Dyslipidemia","enrollment":62},{"nctId":"NCT04304547","phase":"PHASE1","title":"Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-02-04","conditions":"Healthy","enrollment":15},{"nctId":"NCT04258865","phase":"PHASE1","title":"A Clinical Trial to Compare the Pharmacokinetics and Tolerability of CKD-348","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2020-03-25","conditions":"Hypertension, Dyslipidemias","enrollment":30},{"nctId":"NCT04388215","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-10-23","conditions":"Hypertension, Dyslipidemias","enrollment":120},{"nctId":"NCT04272502","phase":"PHASE1","title":"Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-06-04","conditions":"Healthy","enrollment":15},{"nctId":"NCT03726866","phase":"PHASE1","title":"A Study to Investigate Drug-Drug Interaction Between D326, D337 and CKD-828 in Healthy Subjects","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2018-08-31","conditions":"Dyslipidemias, Hypertension","enrollment":30},{"nctId":"NCT02358824","phase":"PHASE1","title":"CKD-828 (80/5mg) Pharmacokinetic Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-02","conditions":"Hypertension","enrollment":48},{"nctId":"NCT02250833","phase":"PHASE1","title":"CKD-828 (80/5mg) Pharmacokinetic Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-09","conditions":"Hypertension","enrollment":69},{"nctId":"NCT01983735","phase":"PHASE3","title":"Efficacy and Safety of TELMINUVO to Stage 2 Hypertension","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2014-01","conditions":"Hypertension","enrollment":200},{"nctId":"NCT01634295","phase":"PHASE3","title":"Efficacy and Safety of CKD-828 to Stage 2 Hypertension","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2012-07","conditions":"Hypertension","enrollment":103},{"nctId":"NCT01501253","phase":"PHASE3","title":"CKD-828 S-Amlodipine Non-Responder Trial","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-08","conditions":"Hypertension","enrollment":187},{"nctId":"NCT01426100","phase":"PHASE3","title":"CKD-828 Telmisartan Non-Responder Trial","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-08","conditions":"Hypertension","enrollment":183},{"nctId":"NCT01356017","phase":"PHASE1","title":"CKD-828 Drug Interaction Study (Telmisartan)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-06","conditions":"Healthy Male Volunteers","enrollment":32},{"nctId":"NCT01356043","phase":"PHASE1","title":"CKD-828 Drug Interaction Study (S-amlodipine)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-05","conditions":"Healthy Male Volunteers","enrollment":24},{"nctId":"NCT01352689","phase":"PHASE1","title":"CKD-828(80/2.5mg) Pharmacokinetic Study_2nd","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-04","conditions":"Hypertension","enrollment":67},{"nctId":"NCT01340131","phase":"PHASE1","title":"CKD-828 (40/5mg) Pharmacokinetic Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-01","conditions":"Hypertension","enrollment":68},{"nctId":"NCT01128322","phase":"PHASE2","title":"CKD-828 Primary Hypertension Trial(Dose-selection)","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-07","conditions":"Hypertension","enrollment":430},{"nctId":"NCT01246193","phase":"PHASE1","title":"CKD-828(80/2.5mg) Pharmacokinetic Study","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2010-11","conditions":"Hypertension","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Telminuvo"],"phase":"phase_3","status":"active","brandName":"CKD-828","genericName":"CKD-828","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-828 is a dual VEGFR2/FGFR1 tyrosine kinase inhibitor that blocks angiogenesis and fibroblast growth factor signaling to inhibit tumor growth. Used for Advanced or metastatic solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}